April 26th 2024
Petros also announced that it has received positive feedback from the FDA after the agency’s informal review of Petros’ technology component for self-selection.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Uro Pipeline: Phase IIb study begins for intraprostatic localized PCa drug
June 27th 2017Other pipeline developments include a new company formed to develop OAB treatments, a phase III urothelial cancer study meeting its primary endpoint, the formation of a partnership to study RCC treatment, and more.
Study: Consumer ads prompt men to seek TRT
May 4th 2017Findings of an ecologic study indicate that direct-to-consumer advertising for testosterone therapy influenced men to seek treatment and was accompanied by increased testosterone prescribing, including initiation in men without clear indications for use.
Transgender surgery: Videos demonstrate cutting-edge techniques
In these videos, expert surgeons demonstrate robot-assisted penile inversion vaginoplasty, single-stage metoidioplasty, and simple orchiectomy for transgender patients.
Testosterone therapy's big week: One urologist's perspective
March 16th 2017Abraham Morgentaler, MD, shares why the recent publication of five studies on testosterone therapy in JAMA and JAMA Internal Medicine "was arguably the most important week ever for the science of testosterone therapy and its impact on men's health."
Uro Pipeline: FDA accepts biologics license application for bladder Ca agent
January 13th 2017Other pipeline developments discussed include an implantable device for OAB treatment, a subcutaneous hypogonadism treatment, efficacy results for an HPV drug, and the status of a device-based BPH treatment.
Uro Pipeline: FDA committee votes in favor of nocturia treatment approval
November 1st 2016Other pipeline developments discussed in this article include the initiation of an intravesical bladder cancer study, a gel treatment for ED that has met its primary endpoint, a patent awarded for the first rechargeable implantable SNM along with some other advancements.
Hypogonadism raises cuff erosion risk in AUS patients
October 25th 2016Hypogonadism in men undergoing artificial urinary sphincter (AUS) implantation significantly increases the risk of cuff erosion, according to the results of a study presented by urologists from UT Southwestern Medical Center, Dallas.
Study questions use of pre-op cultures to prevent prosthetic infection
September 28th 2016In this video, Dr. Nicholas Kavoussi sits down with Dr. Arthur L. Burnett, II, of the Urology Times Editorial Council to discuss his 2016 AUA presentation, "Preoperative urine cultures for prosthetic urological surgery: What is the evidence?"
Readers react to blog post about transgender community
August 30th 2016The recent blog post, “The transgender community: Urology has a role and a responsibility,” by Henry Rosevear, MD, prompted comments from several readers. Given the interest in this topic, Urology Times has compiled these comments.
Sexual Function/Dysfunction: Mixed results with CCH in Peyronie's
July 20th 2016Sexual function/dysfunction topics discussed at the 2016 AUA included the findings of multiple studies on the effects of collagenase clostridium histolyticum (Xiaflex) treatment for Peyronie's disease, causes and treatments for ED, along with a study on patient satisfaction with implantable penile prostheses.